Vizgen co-founder David Walt, a professor at Harvard Medical School, has invested in the spinout as part of its series B round.
Vizgen, a US-based single-cell spatial genomics information technology developer spun out of Harvard University, has raised $37m in a series B round featuring one of its co-founders, Prof David Walt.
Novalis LifeSciences and Northpond Ventures co-led the round, which also attracted Arch Venture Partners, Tao Capital Partners, Pure Vida Investments and an unnamed US endowment fund.
Vizgen is working on genomic profiling tools that allow massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at…
